Sort
30,917 grants matching “tumor microenvironment”
Therapeutic Targeting of RNA Splicing in Triple-Negative Breast Cancer
$714,768Thomas Westbrook · Baylor College Of Medicine · R01 · FY2025 · CA
Three-dimensional Scaffold-based Systems for Primary Human Intestinal Culture
$714,549Calvin J Kuo · Stanford University · R01 · FY2011 · DK
Three-dimensional Scaffold-based Systems for Primary Human Intestinal Culture
$714,549Calvin J Kuo · Stanford University · R01 · FY2012 · DK
Therapeutic targeting MDSC-mediated immune suppression in cancer
$714,368Yulia Nefedova · Wistar Institute · R01 · FY2022 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens
$714,330Rosalie C Sears · Oregon Health & Science University · U01 · FY2021 · CA
Molecular Profiling of the Tumor Microenvironment in Prostate Cancer Progression
$714,317Natasha Kyprianou · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
(PQD5) Avatar-directed Treatment for Ovarian Cancer
$714,297Saravut Weroha · Mayo Clinic Rochester · R01 · FY2017 · CA
(PQD5) Avatar-directed Treatment for Ovarian Cancer
$714,297Saravut Weroha · Mayo Clinic Rochester · R01 · FY2016 · CA
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
$714,132Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2020 · CA
Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification
$714,110Christopher Y Park · New York University School Of Medicine · R01 · FY2025 · CA
Smart and self-reporting clinical nano carriers for drug delivery
$713,953Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Homologous recombination repair pathway mutations and genetic mechanisms shaping anti-tumor immunity and immunotherapy efficacy
$713,601Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$713,488Yi Lin · Mayo Clinic Rochester · R01 · FY2021 · CA
A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors
$713,380Susann M Brady-Kalnay · Case Western Reserve University · R01 · FY2021 · CA
Role of inflammation, innate resistance, and immunity in carcinogenesis
$713,277Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$713,044Ming You · Methodist Hospital Research Institute · R01 · FY2021 · CA
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$713,011Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$712,992Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$712,992Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
$712,871Daniel B Stetson · University Of Washington · R01 · FY2025 · CA
Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
$712,735Sarmad Sadeghi · University Of Southern California · R01 · FY2025 · CA
[PQC-3] A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis
$712,729Hirak S. Basu · University Of Wisconsin-Madison · R01 · FY2015 · CA
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR
$712,726Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes
$712,661Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2022 · DK
Novel Markers for Disease Outcome in Breast Cancer
$712,287Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA